Purple Biotech: The Warrant Overhang, The ADS Ratio, And What It Does To The Financing Path

Where The Main Article Stopped, And What This Follow-Up Isolates

The main article argued that IM1240 bought Purple time, but not a financing solution. This follow-up isolates the layer that is easiest to miss on a fast read of the 20-F: the capital structure itself has become one of the main products the market is pricing.

This is no longer just a question of whether another financing round will come later. As of March 18, 2026 Purple had 1.859 billion issued and outstanding ordinary shares, while non-listed warrants covered 1,273,129 ADS representing 2.545 billion ordinary shares. In plain terms, the warrant layer is already larger than the existing share base. Once that happens, the stock is no longer trading only against cash and pipeline value. It is also trading against the memory of how much more paper can still open above it.

That story sits exactly at the listing junction. On October 16, 2025 Nasdaq notified Purple that it was out of compliance with the minimum bid-price rule. On March 2, 2026 the company changed the ADS ratio again, and on March 16 it received written confirmation that compliance had been regained. That was an effective short-term fix, but it also made clear that the U.S. listing is no longer just a visibility layer. It is part of the financing mechanism itself.

That chart is the core of the continuation. Even if no warrant is exercised tomorrow morning, the market already has to price the possibility of a combined equity base of roughly 4.4 billion ordinary shares. That is not a technical footnote. It is the frame through which any future financing has to be read.

The Warrant Layer Did Not Appear By Accident, It Shows How Purple Could Raise Money

The way Purple funded itself over the last two years matters as much as the amounts. It shows what kind of capital the market was willing to provide, and on what terms.

In September 2025 the company raised $6 million gross. But this was not a clean ADS issuance. The package included 305.5 thousand ADS, pre-funded warrants for 294.5 thousand ADS of which 188.5 thousand were exercised before closing, and 1.2 million ordinary warrants with a $10 exercise price per ADS. In addition, 42 thousand placement-agent warrants were issued with a $12.50 exercise price. That is the core of the current warrant layer.

Before that, in July 2024, Purple raised $2 million gross through a warrant-inducement transaction. Existing warrants were exercised at a reduced $72 price per ADS, and in return the company issued a new reload layer: 24,897 Series A-1 warrants, 31,438 Series A-2 warrants, both at an $80 exercise price, plus 1,972 placement-agent warrants at $90.

In December 2024 the company added a $2.83 million gross registered direct offering, together with 3,309 placement-agent warrants at $75. Alongside that, throughout 2025, the old ATM program with Jefferies sold another 439,836 ADS at an average price of only $2.7, for $1.13 million gross. By contrast, as of March 18, 2026 no ADS had yet been sold under the new Wainwright ATM agreement.

The implication is straightforward: Purple's financing path has already moved from plain equity issuance to layered structures. Low-price ATM sales, equity offerings bundled with warrants, and inducement transactions that create a fresh warrant layer. That does not mean the company had no access to the market. It means the access was expensive in capital-structure terms.

The chart sharpens another point. The September 2025 raise was not only the largest. It also added almost the entire warrant burden that now hangs above the stock. So the discussion about dilution is not historical. It is really a discussion about the terms on which the market most recently agreed to fund the company.

This Is Not Only Future Dilution, The Warrant Layer Already Sits On The Balance Sheet And In Finance Income

The most interesting part is that Purple's warrants are not only a theoretical future threat to shareholders. In the 2025 statements they are classified as derivative liabilities because in a Fundamental Transaction they carry a cash-settlement feature. As a result, year-end 2025 included a $4.066 million warrant liability.

That matters because the warrant layer hits twice. First, it sits above the future share base. Second, it is already moving through the statements via fair-value remeasurement. The company explicitly says that the improvement in finance income, net in 2025 came mainly from changes in the fair value of outstanding warrants. In other words, reported financing results are already absorbing the capital structure.

Put next to the other numbers, the scale becomes clearer. Year-end cash and short-term deposits were $9.574 million. Operating cash use was $5.656 million. The warrant liability was $4.066 million. These are not identical accounting buckets, but the proportions still matter: the warrant liability alone is about 42% of year-end cash and deposits.

One more detail is easy to miss. On March 18, 2026 BNY held 1.554 billion ordinary shares in custody, representing 84% of the outstanding ordinary shares, through the ADS program. That means the ADS line is not a thin U.S. coating on top of an Israeli share. It is the main holding channel for the public equity. So any change in ratio, listing rules, or ability to sell ADS through an ATM directly touches the financing infrastructure, not only investor optics.

The ADS Ratio Change Bought Time, But It Also Reduced The Number Of Clean Moves Left

Purple knew in 2025 that the Nasdaq price line was an active problem. On October 16 it received a non-compliance notice because the ADS had closed below $1 for 30 consecutive trading days. The cure window ran until April 14, 2026. On March 2, 2026 the company moved from one ADS representing 200 ordinary shares to one ADS representing 2,000 ordinary shares. Between March 2 and March 13 the closing price remained above $1 per ADS, and on March 16 Nasdaq confirmed that compliance had been regained.

On the surface that closes the file. In practice it opens the next one. Nasdaq states explicitly that if the company falls out of compliance again within one year of the most recent ratio change, it will not receive another cure period. It will receive a delisting decision. Nasdaq also tightened the rules around repeated reverse actions, warning that companies with cumulative reverse-split ratios of 250-to-1 or more over two years may lose the cure-period path as well.

That is where the financing pressure becomes more serious. Since August 2020, each ADS has moved from representing 1 ordinary share to 10, then in September 2024 from 10 to 200, and in March 2026 from 200 to 2,000. The ratio lever has already been used repeatedly. It solved yesterday's problem, but it looks less and less like a clean tool that can be used again without side effects.

That is the difference between compliance and financeability. Temporary compliance with the bid-price rule keeps the company on Nasdaq. It does not erase the fact that this channel has already gone through two sharp ratio moves in a fairly short period. Any discussion of future capital raising therefore has to assume that the U.S. listing still matters a great deal, but that it is also more fragile than before.

Nasdaq added another layer of uncertainty in January 2026 by proposing a continued-listing rule based on at least $5 million of market value of listed securities. That rule was proposed, not adopted. But the proposal itself signals where the regulatory mood is going: the exchange is less comfortable with very small names surviving mainly through ratio engineering.

What This Does To The Financing Path

The fair reading is that Purple still has time. At the end of 2025 it held about $9.6 million of cash and short-term deposits, and management says that is sufficient for at least the next 12 months. At that date the company also had no borrowings. In parallel, the January 2026 IM1240 announcement delivered a toxicology milestone, and the company continues to aim for a regulatory filing in the second half of 2026.

But that time is not clean. If one reads 2025 as an ordinary biotech year, it is easy to think the next financing is only a function of milestones. That is incomplete. At Purple, the warrant layer, the ADS structure, and the Nasdaq listing now also determine the price at which every milestone can be converted into capital.

The company itself says that long-term capital needs depend among other things on further CAPTN-3 development, the ability to commercialize or out-license programs, and the ability to obtain more financing. So the likely financing path now rests on three cumulative conditions:

1. Maintain stable Nasdaq listing without sliding back too quickly into another ADS-ratio discussion.
2. Turn IM1240 progress into partnership, licensing, or external funding that does not rely only on new equity issuance.
3. Avoid a situation in which the warrant layer becomes the almost exclusive bridge tool, because then every fresh financing only pushes more weight above the share base.

Even the short-interest data reinforce that reading. On March 27, 2026 short float was only 0.02% and SIR was 0.14, well below the sector averages of 0.38% and 1.278. So there is no unusually crowded short creating special technical pressure, but there is also no squeeze layer that can hold the stock up by force. The market is not signaling a major short battle. It is signaling that the issue is financing structure, not short-seller combat.

Bottom Line

The bottom line is that Purple's capital structure has already moved beyond the point where it can be treated as a technical side note. The warrant layer is larger than the current share base, it sits as a $4.066 million liability on the balance sheet, and it depends on an ADS channel that has already needed another ratio change to preserve listing. That does not mean the company has no time. It does mean that the time it has is expensive.

The strongest counter-thesis is that this reading may be too severe. If IM1240 keeps hitting milestones and the company succeeds in generating real strategic interest or a partnership, the warrants may be seen not as dead weight but as a potential source of capital. The current cash position and the absence of borrowings also give Purple a real operating window.

For now, though, Purple's financing path looks more like a capital-structure test than a pure science test. The key to the next reports and announcements will not only be whether another milestone is positive, but whether that milestone opens a cleaner capital channel than the one the company has had to use up to now.